Lopinavir/ritonavir (LPV/r) is recommended by the World Health Organization as first-line treatment for HIV-infected infants and young children. We performed a composite population pharmacokinetic (PK) analysis on LPV plasma concentration data from 6 pediatric and adult studies to determine maturation and formulation effects from infancy to adulthood.Intensive PK data were available for infants,children,adolescents,and adults (297 intensive profiles/1662 LPV concentrations). LPV PK data included 1 adult, 1 combined pediatric-adult, and 4 pediatric studies (age 6 weeks to 63 years) with 3 formulations (gel-capsule, liquid, melt-extrusion tablets). LPV concentrations were modeled using nonlinear mixed effects modeling (NONMEM v. 7.3; GloboMax, Hanover, Maryland) with a one compartment semiphysiologic model. LPV clearance was described by hepatic plasma flow (Q HP ) times hepatic extraction (E H ), with E H estimated from the PK data. Volume was scaled by linear weight (WT/70) 1.0 . Bioavailability was assessed separately as a function of hepatic extraction and the fraction absorbed from the gastrointestinal tract. The absorption component of bioavailability increased with age and tablet formulation. Monte Carlo simulations of the final model using current World Health Organization weight-band dosing recommendations demonstrated that participants younger than 6 months of age had a lower area under the drug concentration-time curve (94.8 vs >107.4 μg hr/mL) and minimum observed concentration of drug in blood plasma (5.0 vs > 7.1 μg/mL) values compared to older children and adults. Although World Health Organization dosing recommendations include a larger dosage (mg/m 2 ) in infants to account for higher apparent clearance, they still result in low LPV concentrations in many infants younger than 6 months of age receiving the liquid formulation.
Lopinavir (LPV) is an established antiretroviral agent commonly used as part of a first-line antiretroviral therapy (ART) in pediatric populations with a liquid formulation suitable for use in term infants as young as 2 weeks of age. 1 It is the preferred protease inhibitor for children in the first 3 years of life. Ritonavir (RTV), also a protease inhibitor and potent cytochrome P450 (CYP) 3A4 inhibitor, is used as a component of ART as a pharmacologic enhancer of many protease inhibitors. Because LPV is a CYP3A substrate and has a short half-life, it is coformulated with RTV, as Kaletra R (LPV/r). Several studies described LPV/r pharmacokinetics (PK) in adults and children. [2] [3] [4] [5] [6] [7] [8] [9] However, no prior comprehensive model has described the dynamic changes in LPV/r PK from infancy into adulthood.
Three distinct formulations available for LPV/r include liquid, soft gel capsule, and melt-extrusion tablet. During the Food and Drug Administration's initial approval, LPV/r was formulated as soft gel capsule and liquid. In later years, the capsule formulation was withdrawn from the market and replaced with a heat-stable and more bioavailable melt-extrusion tablet formulation. 10 Due to difficulties swallowing solid medications, infants and younger children receive the liquid formulation, and the majority of the patients over 6 years of age along with adults receive the tablet formulation. 11 In addition, prior studies demonstrated slower rates of viral suppression in younger infants on LPV/r as compared to older infants and children. 12, 13 thus, understanding PK differences across the ages may provide insight into the mechanism.
The current study aimed to characterize PK differences in LPV disposition from birth through childhood, adolescence, and into adulthood. In doing so, this analysis will also evaluate the effect of LPV formulation on bioavailability of the drug in children and adults.
Methods

Participants
Intensive LPV/r PK data were pooled from 6 completed studies (4 pediatric, 1 adult, and 1 combined pediatric-adult). Institutional review board approval was obtained at each participating site, and written informed consent was completed either by the patient (adult subjects) or legal guardian (pediatric subjects) before any study-specific procedures were initiated.
The pediatric studies were pediatric AIDS Clinical Trials Group P1030, P1038, P1080, P1083, and a pediatric pharmacology research unit (PPRU) study. [14] [15] [16] [17] [18] The adult data sets were derived from P1080 and a protocol of a national study from California Collaborative Treatment Group (CCTG) study 585. 18, 19 Individual study characteristics are described below and presented in Table 1. P1030 was a multicenter, phase I/II longitudinal pediatric study of LPV/r in HIV-1-positive children initiating ART between 2 weeks and 6 months of age. Participants were dosed 300/75 mg/m 2 in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). Intensive LPV/r PK profiles were assessed at 2 weeks after study enrollment and at 1 year of age, with up to 5 plasma samples collected throughout the 12-hour dosing interval of an observed dose. 6, 15 P1038 was a multicenter, phase I/II longitudinal pediatric study of LPV/r in HIV-1-positive children with viral LPV/r resistance ranging from 2 to 18 years of age failing current ART. Participants received increased doses of LPV/r in combination with 2 NRTIs. Intensive LPV/r PK profiles were obtained on 2 to 3 occasions, with up to 6 plasma samples collected throughout the 12-hour dosing interval, which included a baseline and trough after observed dose. 16 P1080 was a multicenter, phase I pediatric and adolescent study that included participants taking psychiatric medications in addition to therapy for HIV-1 (ages ranging from 6 to 25 years). LPV/r was dosed in combination with 2 NRTIs. Intensive LPV/r PK profiles were assessed up to 8 weeks after enrollment, with up to 6 plasma samples collected after the dose, which included a baseline and trough after observed dose.
18
P1083 was a multicenter, phase II/III pediatric longitudinal study that assessed World Health Organization (WHO) LPV/r pediatric weight-band dosing guidelines for HIV-1-positive infants and children 3 to 25 kg between 0.1 and 12.8 years of age. Participants received 2 NRTIs in addition to LPV/r. Intensive LPV/r PK profiles were assessed 4 weeks after the initial treatment, with up to 6 plasma samples collected during the 12-hour dosing interval, which included a baseline and trough after observed dose.
17
CCTG585 was a multicenter, phase IV longitudinal study of the safety and tolerability of once-daily LPV/r dosing (800/200 mg) in HIV-1-positive adults aged 23 to 63 years sequentially given liquid, capsule, and tablet formulations. Participants received 2 NRTIs in addition to LPV/r. Intensive LPV/r PK profiles were collected after roughly 4 weeks of initial treatment, with up to 7 plasma samples collected through the 24-hour dosing interval, which included a baseline and trough after observed dose. 19, 20 The PPRU study was a randomized, open-label, crossover phase IV study that studied LPV/r bioavailability of crushed vs whole tablets in pediatric participants receiving LPV/r in combination with 2 NRTIs. The intensive LPV/r PK profiles of participants taking intact oral melt-extrusion tablets were used for the analysis, with up to 7 plasma samples collected through the 12-hours dosing interval, which included a baseline and trough after observed dose. limits of quantification ࣘ0.10 μg/mL for both LPV and RTV. The studies had an assay coefficient of variation of <15% for the pooled studies.
Pharmacokinetic Analysis A 1-compartment semiphysiologic model using nonlinear mixed-effect modeling was performed using NONMEM R version 7.3 with a GNU Fortan G77 compiler (Gaithersburg LLC, Ellicott City, Maryland). An open 1-compartment model with first-order absorption (ADVAN 2, TRANS2 subroutine) and firstorder conditional estimation method with interaction of clearance (CL) and volume of distribution (Vd) were used to analyze the data. An exponential-normal distribution error model was used to describe betweensubject variability (BSV), and a combination residual error model was used to describe the residual error that could not be explained by the model and could not be attributed to BSV. Participants with multiple intensive PK visits were categorized as separate subjects for the analysis. All drug concentrations were collected after a minimal duration of at least 2 weeks of therapy and were assumed to be at steady state. Participants who were suspected to be nonadherent (predose levels 4 magnitudes lower than the minimum observed concentration of drug in blood plasma [C min ]) were considered a non-steady-state single-dose PK for purposes of the analysis.
This semiphysiologic model included hepatic intrinsic clearance, which was described by the estimated LVP/r ratio extracted by the hepatocytes (E H ) and hepatic plasma flow (Q HP ) ( Figure 1 ). Hepatic plasma flow was estimated as percentage of plasma (55%) multiplied by typical hepatic blood flow (1500 mL/min or 90 L/hr) or 50 L/hr, and allometrically scaled: Q HP = 50 L/hr (WT/70) 0.75 . 21 Vd was scaled by weight (WT) 1.0 . Bioavailability (F) is described as the amount absorbed (F ABS ) and by the ratio escaping hepatic extraction. The model was described by the following equations:
Lopinavir Model With RTV Inhibition
The semiphysiological hepatic extraction model was expanded to describe RTV inhibition of LPV CL using observed RTV concentrations. In the model, RTV concentration was assigned an inhibition equation with the concentration of RTV inhibiting LPV metabolism by 50% (IC 50 ) estimated on the E H impacting both CL and bioavailability (F H ).
Covariate Screening Potential covariates (age, sex, and formulation) were tested in the model: age and sex on F ABS , E H , and Vd; formulation was assessed on F. Potential covariates were added 1 at a time as either a linear or nonlinear function, with covariates that improved the model fitting by change in the objective function value of at least 3.84 (P < .05) being retained in the initial covariate screening. All covariates identified as significant in this phase were then evaluated using a forward selection approach. Covariates found to improve the objective function value of at least 8 (P < .005) were retained in the final model. subjects' PK parameters were generated from the final model using the POSTHOC subroutine. For internal model evaluation, a 1000-sample bootstrap assessment of the final model was performed using Wings 7.3 for NONMEM. A visual predictive check was performed using a simulated population of 1000 patients via NONMEM NSUB routine.
Monte Carlo Simulation
Monte Carlo simulations were performed using the final model to generate PK profiles for 5000 virtual subjects (4000 pediatric and 1000 adults [70 kg and 40 years of age]). Pediatric subjects were assigned a randomly generated weight based on a uniform distribution with median weights from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey age-weight distribution. 22 Subjects with weight less than 35 kg were simulated using WHO weight-band dosing, and those with weight above 35 kg were assigned the adult dosage of 400/100 mg LPV/r tablets. 23 Virtual subjects aged younger than 6 years were assigned to liquid LPV/r formulation and those aged 6 years or older were assigned to the tablet formulation.
Results
Pharmacokinetic Sampling
Intensive PK data were available for 297 infants, children, adolescents, and adults (1662 LPV concentrations) (Figure 2 ). Table 1 summarizes participants and sampling from intensive PK visits. Participants greater than 10 years of age were assigned solid formulation where formulation information was missing. Specifically, in 4 participants without formulation data, the participants were assigned gel-capsule formulation as they were all 16 years of age and gel capsule was the only available solid formulation used in the study. A total of 4 participants with high predose levels were excluded from the analysis, as their self-reported dosing history did not match their PK profile. In addition, 34 subjects (11%) with low predose levels were assumed nonadherent (C min was greater than 4-fold lower than predose) and were treated as single dose for the analysis.
Compartmental Modeling
The semiphysiological hepatic extraction model described the data without significant bias (Figure 3 , A-E). Final PK model parameters and standard error estimates are shown in Table 2 . All parameter estimates were within the 95% confidence interval of the bootstrap data set.
After allometrically scaling for size, the univariate screen identified age and formulation as significant covariates on the absorption component on bioavailability (F ABS ). Age modeled as a rate constant (half-life) best described maturation changes in F ABS (Table 2) . These covariates remained significant in the multivariate screen. The final model includes age as a rate constant effect on F ABS and formulation as a categorical on F (Figure 4, A and B ). The final model demonstrates apparent clearance decreases to half the maximal value at 0.55 years and approaches the adult value at 2 years of age. Liquid formulation resulted in a 19% reduction in bioavailability compared to other formulations.
Finalized Equations:
A separate model using individual subjects' RTV concentrations was also built. RTV inhibition was incorporated in the model as an inhibitory maximal effect (Emax) function on EH affecting both CL and F. Using the same inhibitory function for CL and F provided a good fit to the data; thus, we did not attempt more complicated models with separate inhibitory functions. The in vivo RTV inhibitory concentration (IC 50 ) on E H was estimated to be 1.62 μg/mL. This resulted in an improved objective function value of 61.4, but only marginally reduced BSV from 15.5% to 13.0%. After covariate screening, age and formulation were significant covariates for F ABS similar to the model without individual subjects' RTV concentration. Post hoc analysis of CL/F between the RTV individual observed and RTV individual "ignorant" model yielded a coefficient of determination (R 2 ) value of 0.97 ( Figure S1 ). Although the approach utilizing subjects' RTV concentrations reduced the objective function (Table S1 , Figure S2 ), it has limited predictive clinical utility, as individual subjects' RTV concentrations are not known a priori. Therefore, the RTV ignorant model, which incorporated the general RTV "boosting" effects on LPV but did not require knowledge of the individual RTV concentrations, was used to simulate LPV exposure with WHO dosing.
Monte Carlo Simulation
The Monte Carlo simulation comparison of area under the plasma drug concentration-time curve (AUC) and 12-hour plasma trough concentrations (C min ) obtained with the WHO weight band are shown in Figure 5 , A and B. Subjects older than 6 years of age were transitioned from liquid to tablet dosing. The median AUC values were 94.8, 112.3, 147.9, 116.8, and 107.4 μg • hr/mL and C min were 5.0, 6.5, 9.1, 7.7, and 7.1 μg/mL for age groups <6 months, 6 months to <6 years, 6 to <12 years, 12 to <21 years, and 21 to 40 years, respectively. 
Discussion
Multiple studies have evaluated the PK of LPV/r in pediatric and adult patients including the 3 distinct formulations (liquid, gel capsule, and tablet).
1 LPV is well characterized as a CYP3A substrate and is rapidly metabolized if not administered under CYP inhibitory conditions with bio-inactivation via CYP3A4 and CYP3A5. 24 LPV PK has a high degree of intersubject clearance and bioavailability variability, especially with the developmental factors seen in childhood. Thus, LPV is coformulated with low-dose RTV, a PK enhancing agent to decrease the apparent clearance of LPV, prolong LPV exposure, and maintain a longer duration of effect. 24 Because of its metabolic pathway and coformulation with RTV, LPV/r has multiple drugdrug interactions with medications commonly used in HIV-infected patients. 21 Our study, which pooled data from 6 prior studies of infants, children, and adults, represents the largest population PK analysis of LPV to date. We utilized a semiphysiologic hepatic extraction model rather than the standard PK model with the aim of better characterizing the inhibition of CYP3A(4) enzymes through the administration of this RTV-boosted antiretroviral drug formulation which impacts both bioavailability and clearance. The semiphysiologic hepatic extraction model has the benefit of linking both bioavailability and clearance to hepatic enzyme activity. Our model showed that both age and formulation were independent predictors of bioavailability. The model predicted a decrease in apparent clearance (CL/F) from 0.31 L/hr/kg in the youngest subject receiving liquid formulation to 0.080 L/hr/kg for adults receiving the tablet formulation. Using the median weight (20.5 kg) and age (7.4 years) from the pooled studies, median apparent CL was 0.082 L/hr/kg for a 20.5-kg and 7.4-year old average subject. The age effect accounted for a 49% change in CL/F over the range of ages seen in the study and occurred predominantly in the first 2 years.
The results from our study are reflective of other prior studies (Table 3 ) of pediatric and adult populations. Using a typical 6-year-old child (weight = 20 kg) as a comparator, the hepatic extraction model predicted a weight-adjusted apparent clearance of 0.102 L/hr/kg and 0.082 L/hr/kg for those receiving liquid formulation and tablet formulation, respectively. These results are comparable to those found in other LPV/r pediatric studies. Similar results were seen in adult data studies using a 40-year-old (weight = 70 kg) patient as the comparator.
The Monte Carlo simulation of the final model using WHO weight-band dosing, demonstrated that both AUC and C min increase with age throughout childhood due to increased bioavailability with age and the transition to tablet formation. In this weight-band dosing simulation, there was a decreased exposure of LPV in the youngest age group and a significantly lower exposure with the liquid LPV formulation. In addition, a significant number of patients in early infancy (<6 months of age and <10 kg) had low LPV trough concentrations (C min ࣘ1 μg/mL at 12 hours) compared to older children, adolescents, and adults. This could be due to the decreased RTV exposure in those patients, which increases LPV clearance. Thus, higher LPV/r doses may be required in infants younger than 6 months of age. This is consistent with the observation that younger infants have slower viral decline following ART therapy.
12,13 thus, maturational differences in PK likely contribute to this observed clinical effect.
The semiphysiological hepatic extraction model allows the calculation of an RTV in vivo IC 50 to determine the degree of CYP inhibition. While the final hepatic extraction model used for the simulation did not include individual RTV concentrations, we also developed a model that integrated RTV inhibition based on individual subjects' RTV concentrations. While the incorporation of RTV inhibition significantly reduced the objective function of the model, it did not lead to the discovery of additional covariates nor significantly reduced BSV. RTV concentrations are not known a priori and thus cannot be used as a ·C L predictive factor to optimize LPV/r dosing for individual patients, nor can it be used for general dosing recommendations. As such, for clinical interpretation, the final model is RTV concentration "ignorant" and does not require knowledge of the actual ritonavir concentrations for simulations of LPV, but still incorporates the general effect of RTV in inhibiting LPV metabolism.
The extent of the oral bioavailability of LPV/r is dependent on many physiological factors including stability of the formulations, food-drug interactions, transit time through the gastrointestinal tract, and firstpass metabolism, which are difficult to characterize with the semiphysiologic model. LPV/r can have increased F when taken with a meal, especially with fatty food, and the transition from a liquid to solid diet in older infants may account for the majority of the agerelated changes in F ABS and thus CL/F seen in the current study. 25 Given the variable and unpredictable absorption characteristics, especially in the pediatric population, alternative formulations are currently being explored to replace the less stable liquid LPV/r formulation. A new formulation of LPV/r sprinkles was evaluated in the Children with HIV in AfricaPharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS-2) trial for children aged 3 months to 13 years. 26 The generic formulation was not bioequivalent to the Food and Drug Administration approved liquid formulation having increased LPV/r levels compared to the liquid formulations, but decreased exposure compared to the melt-extrusion tablet formulation. 26 The WHO approved this formulation, but it is not currently Food and Drug Administration approved. 27 The sprinkle formulation was not assessed in the current study.
Prior population PK LPV/r models in adults have evaluated other factors such as albumin, α1-acid glycoprotein levels, liver function, and potential drugdrug interactions as potential covariates. 3, 4, 8 Many of these covariates could have a significant effect on LPV PK due to developmental changes from infancy to adolescence. For example, the increased production of albumin and α1-acid glycoprotein during early life could affect LPV/r binding and drug-drug interactions. Because protein binding and concurrent drug were not universally available in the current data sets, these potential effects were not explored. The model was also limited in that it was difficult to separate age from formulation effects, as most patients transitioned to tablet formulation around the age of 6. In addition, in the 1 study with once-daily administration, the LPV concentrations collected 24 hours after the dose were overpredicted by the model, likely due to waning RTV inhibition. Thus, the current model is representative of LPV/r pharmacokinetics following standard every-12-hour administration. Between-subject variability was not included on KA, as there was limited early PK sample collection during the absorption phase. Between-subject variability was also not assessed on F ABS due to difficulty in parsing from F H , which incorporates BSV from E H . Finally, the typical population blood flow and hematocrit values used in this analysis may vary from those in patients with HIV infection and may have biased our estimate of E H . 21 
Conclusions
In conclusion, the current population PK analysis represents the most comprehensive analysis of the role of age and formulation on LPV disposition to date, characterizing clearance changes from birth to middleaged adulthood. In our study, we found a dramatic decrease in CL/F over the first 2 years of life and an increase in bioavailability with the transition from liquid to tablet formulation. The WHO weight-band dosing simulation shows potential for low LPV concentration in early infancy with currently recommended dosing and may require further evaluation for improved dosing recommendations adjusted for newly available LPV/r pediatric formulations such as sprinkles. The current composite pharmacologic model can be used for simulations to better characterize and assess LPV/r dosing regimens across all age groups.
